The DOI matches its Crossref record; 32 of the 34 references it cites were found in a registry or an index.
MDS clinical diagnostic criteria for Parkinson’s disease
Abstract
This document presents the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease (PD). The Movement Disorder Society PD Criteria are intended for use in clinical research but also may be used to guide clinical diagnosis. The benchmark for these criteria is expert clinical diagnosis; the criteria aim to systematize the diagnostic process, to make it reproducible across centers and applicable by clinicians with less expertise in PD diagnosis. Although motor abnormalities remain central, increasing recognition has been given to nonmotor manifestations; these are incorporated into both the current criteria and particularly into separate criteria for prodromal PD. Similar to previous criteria, the Movement Disorder Society PD Criteria retain motor parkinsonism as the core feature of the disease, defined as bradykinesia plus rest tremor or rigidity. Explicit instructions for defining these cardinal features are included. After documentation of parkinsonism, determination of PD as the cause of parkinsonism relies on three categories of diagnostic features: absolute exclusion criteria (which rule out PD), red flags (which must be counterbalanced by additional supportive criteria to allow diagnosis of PD), and supportive criteria (positive features that increase confidence of the PD diagnosis). Two levels of certainty are delineated: clinically established PD (maximizing specificity at the expense of reduced sensitivity) and probable PD (which balances sensitivity and specificity). The Movement Disorder Society criteria retain elements proven valuable in previous criteria and omit aspects that are no longer justified, thereby encapsulating diagnosis according to current knowledge. As understanding of PD expands, the Movement Disorder Society criteria will need continuous revision to accommodate these advances. © 2015 International Parkinson and Movement Disorder Society
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD was diagnosed by two neurologists according to Postuma et al., criteria. 4”
From Validation of differentially expressed brain‐enriched microRNAs in the plasma of PD patients (2020) · cites this paper as [4]
In the citing paper
“Final diagnoses were based on internationally established criteria [12, 46, 49–52].”
In the citing paper
“PD is the second most common neurodegenerative disorder and is defined by the presence of motor symptoms including bradykinesia, rigidity, and resting tremor (Postuma et al., 2015).”
From Microbiome–microglia connections via the gut–brain axis (2019) · cites this paper as Postuma et al., 2015
In the citing paper
“The final diagnosis of PD, MSA, and PSP was determined by two neurologists according to the updated clinical guidelines[37-40].”
From QEEG Signatures are Associated with Nonmotor Dysfunctions in Parkinson's Disease and Atypical Parkinsonism: An Integrative Analysis (2023) · cites this paper as [39]
In the citing paper
“PD patients present with tremors, bradykinesia and rigidity, with atrophy initially observed in the substantial nigra and brainstem, progressing to the basal ganglia and related subcortical regions over the course of the disease (Postuma et al., 2015).”
From Thinking versus feeling: How interoception and cognition influence emotion recognition in behavioural-variant frontotemporal dementia, Alzheimer's disease, and Parkinson's disease (2023) · cites this paper as Postuma et al., 2015
In the citing paper
“Diagnosis was established by the multidisciplinary teams at each research institute based on current consensus diagnostic criteria (McKhann et al., 2011; Postuma et al., 2015; Rascovsky et al., 2011).”
From Thinking versus feeling: How interoception and cognition influence emotion recognition in behavioural-variant frontotemporal dementia, Alzheimer's disease, and Parkinson's disease (2023) · cites this paper as Postuma et al., 2015
Citations
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536
Self-citationSensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationThe relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Second consensus statement on the diagnosis of multiple system atrophy
Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Dürr, A., Fowler, C. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000324625.00404.15 · Cited by 3,140
Self-citationDiagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
MDS research criteria for prodromal Parkinson's disease
Berg, D., Postuma, R. B., Adler, C. H., Bloem, B. R., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G. M., Joseph, L., et al. (2015) · Movement Disorders · doi:10.1002/mds.26431 · Cited by 1,394
Self-citationThe accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service
Hughes, A. J., Daniel, S. E., Ben‐Shlomo, Y., & Lees, A. J. (2002) · Brain · doi:10.1093/brain/awf080 · Cited by 1,258
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I. G., Quinn, N. P., Sethi, K. D., Shults, C. W., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,011
Self-citation
Flagged first, then by citations
2 of the 34 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Self-citationDiagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Self-citationBloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Self-citationDiagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Epidemiology of Parkinson’s disease
Tysnes, O., & Storstein, A. M. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1686-y · Cited by 2,437
Challenges in the diagnosis of Parkinson's disease
Tolosa, E., Garrido, A., Scholz, S. W., & Poewe, W. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00030-2 · Cited by 1,874
Self-citationBalestrino, R., & Schapira, A. H. V. (2020) · European Journal of Neurology · doi:10.1111/ene.14108 · Cited by 1,508
Parkinson disease-associated cognitive impairment
Aarsland, D., Batzu, L., Halliday, G. M., Geurtsen, G. J., Ballard, C. G., Chaudhuri, К. R., & Weintraub, D. A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00280-3 · Cited by 1,540
Self-citationMDS research criteria for prodromal Parkinson's disease
Berg, D., Postuma, R. B., Adler, C. H., Bloem, B. R., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G. M., Joseph, L., et al. (2015) · Movement Disorders · doi:10.1002/mds.26431 · Cited by 1,394
Self-citationParkinson’s disease: etiopathogenesis and treatment
Jankovic, J. J., & Tan, E. K. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322338 · Cited by 1,273
Postuma, R. B., Iranzo, Á., Hu, M., Högl, B., Boeve, B. F., Manni, R., Oertel, W. H., Arnulf, I., Ferini‐Strambi, L., Puligheddu, M., et al. (2019) · Brain · doi:10.1093/brain/awz030 · Cited by 1,189
Self-citationDopamine: Functions, Signaling, and Association with Neurological Diseases
Klein, M. O., Battagello, D. S., Cardoso, A. R., Hauser, D. N., Bittencourt, J. C., & Correa, R. G. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-018-0632-3 · Cited by 1,073
The pathogenesis of Parkinson's disease
Morris, H. R., Spillantini, M. G., Sue, C. M., & Williams‐Gray, C. H. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01478-2 · Cited by 1,164
Cognitive decline in Parkinson disease
Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.27 · Cited by 1,027
The epidemiology of Parkinson's disease
Ben-Shlomo, Y., Darweesh, S., Llibre-Guerra, J., Marras, C., San Luciano, M., & Tanner, C. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01419-8 · Cited by 967
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
“However, the major problem in the differential diagnosis of atypical parkinsonism with PD remains the well-recognized fact that a large number of patients with atypical parkinsonism will not present with these hallmark features early or ever during the course of the disease.(17) This phenotypic variability, the increa…”
InfluentialSelf-citationThe Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy
Wenning, G. K., Stanković, I., Vignatelli, L., Fanciulli, A., Buonaura, G. C., Seppi, K., Palma, J., Meissner, W. G., Krismer, F., Berg, D., et al. (2022) · Movement Disorders · doi:10.1002/mds.29005 · Cited by 845
Self-citationCalabresi, P., Mechelli, A., Natale, G., Volpicelli‐Daley, L. A., Lazzaro, G. D., & Ghiglieri, V. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05672-9 · Cited by 930
Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study
Horsager, J., Andersen, K. B., Knudsen, K., Skjærbæk, C., Fedorova, T. D., Okkels, N., Schaeffer, E., Bonkat, S. K., Geday, J., Otto, M., et al. (2020) · Brain · doi:10.1093/brain/awaa238 · Cited by 782
Self-citationSu, D., Cui, Y., He, C., Yin, P., Bai, R., Zhu, J., Lam, J. S. T., Zhang, J., Yan, R., Zheng, X., et al. (2025) · BMJ · doi:10.1136/bmj-2024-080952 · Cited by 751
Simuni, T., Chahine, L. M., Poston, K. L., Brumm, M. C., Buracchio, T., Campbell, M., Chowdhury, S., Coffey, C. S., Concha‐Marambio, L., Dam, T., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00405-2 · Cited by 685
Self-citationThe Synucleinopathies: Twenty Years On
Goedert, M., Jakes, R., & Spillantini, M. G. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-179005 · Cited by 590
A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria
Höglinger, G. U., Adler, C. H., Berg, D., Klein, C., Outeiro, T. F., Poewe, W. H., Postuma, R. B., Stoessl, A. J., & Lang, A. E. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00404-0 · Cited by 607
Self-citationReich, S. G., & Savitt, J. M. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.014 · Cited by 553
Microbiome–microglia connections via the gut–brain axis
Abdel-Haq, R., Schlachetzki, J. C. M., Glass, C. K., & Mazmanian, S. K. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20180794 · Cited by 471
Rossi, M., Candelise, N., Baiardi, S., Capellari, S., Giannini, G., Orru, C. D., Antelmi, E., Mammana, A., Hughson, A. G., Buonaura, G. C., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02160-8 · Cited by 470
Groveman, B. R., Orru, C. D., Hughson, A. G., Raymond, L. D., Zanusso, G., Ghetti, B. F., Campbell, K. J., Safar, J., Galasko, D. R., & Caughey, B. W. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0508-2 · Cited by 414
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
Henrich, M. T., Oertel, W. H., Surmeier, D. J., & Geibl, F. F. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00676-7 · Cited by 450
Self-citationOn Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease
Giguère, N., Burke, S., & Trudeau, L. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00455 · Cited by 434
Prodromal Parkinson disease subtypes — key to understanding heterogeneity
Berg, D., Borghammer, P., Fereshtehnejad, S.-M., Heinzel, S., Horsager, J., Schaeffer, E., & Postuma, R. B. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00486-9 · Cited by 409
Self-citationAdvances in markers of prodromal Parkinson disease
Postuma, R. B., & Berg, D. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.152 · Cited by 422
Self-citationMachine Learning for the Diagnosis of Parkinson's Disease: A Review of Literature
Mei, J., Desrosiers, C., & Frasnelli, J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.633752 · Cited by 441
Tanner, C. M., & Ostrem, J. L. (2024) · New England Journal of Medicine · doi:10.1056/nejmra2401857 · Cited by 438
Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?
Jellinger, K. A., & Korczyn, A. D. (2018) · BMC Medicine · doi:10.1186/s12916-018-1016-8 · Cited by 406
Gilron, R., Little, S., Perrone, R., Wilt, R., de Hemptinne, C., Yaroshinsky, M. S., Racine, C. A., Wang, S. S., Ostrem, J. L., Larson, P. S., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00897-5 · Cited by 343
Evolution of prodromal Parkinson’s disease and dementia with Lewy bodies: a prospective study
Fereshtehnejad, S., Yao, C. W., Pelletier, A., Montplaisir, J. Y., Gagnon, J., & Postuma, R. B. (2019) · Brain · doi:10.1093/brain/awz111 · Cited by 373
Self-citationMeta‐Analysis of Gut Dysbiosis in Parkinson's Disease
Nishiwaki, H., Ito, M., Ishida, T., Hamaguchi, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Shimamura, T., Mori, H., et al. (2020) · Movement Disorders · doi:10.1002/mds.28119 · Cited by 370
Chen, Z., Li, G., & Liu, J. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104700 · Cited by 364
Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson’s disease
Ding, X., Wang, X., Xia, D., Liu, H., Tian, H., Fu, Y., Chen, Y., Qin, C., Wang, J.-Q., Zhang, Z., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01198-1 · Cited by 375
Goud, K. Y., Moonla, C., Mishra, R. K., Yu, C., Narayan, R. J., Litvan, I., & Wang, J. (2019) · ACS Sensors · doi:10.1021/acssensors.9b01127 · Cited by 358
Self-citationNeuropathology and molecular diagnosis of Synucleinopathies
Koga, S., Sekiya, H., Kondru, N., Ross, O. A., & Dickson, D. W. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00501-z · Cited by 347
Iranzo, Á., Fairfoul, G., Ayudhaya, A. C. N., Serradell, M., Gelpí, E., Vilaseca, I., Sánchez‐Valle, R., Gaig, C., Santamaría, J., Tolosa, E. S., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30449-x · Cited by 335
Knudsen, K., Fedorova, T. D., Hansen, A. K., Sommerauer, M., Otto, M., Svendsen, K. B., Nahimi, A., Stokholm, M. G., Pavese, N., Beier, C. P., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30162-5 · Cited by 309
Brakedal, B., Dölle, C., Riemer, F., Ma, Y., Nido, G. S., Skeie, G. O., Craven, A. R., Schwarzlmüller, T., Brekke, N., Diab, J., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.001 · Cited by 323
Propagative α-synuclein seeds as serum biomarkers for synucleinopathies
Okuzumi, A., Hatano, T., Matsumoto, G., Nojiri, S., Ueno, S., Imamichi, Y., Kimura, H., Kakuta, S., Kondo, A., Fukuhara, T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02358-9 · Cited by 331
Validation of the MDS clinical diagnostic criteria for Parkinson's disease
Postuma, R. B., Poewe, W., Litvan, I., Lewis, S., Lang, A. E., Halliday, G., Goetz, C. G., Chan, P., Slow, E., Seppi, K., et al. (2018) · Movement Disorders · doi:10.1002/mds.27362 · Cited by 283
Self-citationAlpha‐Synuclein as a Biomarker for Parkinson's Disease
Atik, A., Stewart, T., & Zhang, J. (2016) · Brain Pathology · doi:10.1111/bpa.12370 · Cited by 311
Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease
Spina, S., La Joie, R., Petersen, C., Nolan, A. L., Cuevas, D., Cosme, C., Hepker, M., Hwang, J.-H., Miller, Z. A., Huang, E. J., et al. (2021) · Brain · doi:10.1093/brain/awab099 · Cited by 278
Attems, J., Toledo, J. B., Walker, L., Gelpí, E., Gentleman, S., Halliday, G. M., Hortobágyi, T., Jellinger, K. A., Kovács, G. G., Lee, E. B., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02255-2 · Cited by 295
Self-citationRandomized Trial of Focused Ultrasound Subthalamotomy for Parkinson’s Disease
Martínez‐Fernández, R., Máñez-Miró, J. U., Rodríguez‐Rojas, R., del Álamo, M., Shah, B., Hernández‐Fernández, F., Pineda‐Pardo, J. A., Monje, M. H. G., Fernández‐Rodríguez, B., Sperling, S. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2016311 · Cited by 296
Self-citationThe vermiform appendix impacts the risk of developing Parkinson’s disease
Killinger, B. A., Madaj, Z., Sikora, J. W., Rey, N. L., Haas, A. J., Vepa, Y., Lindqvist, D., Chen, H., Thomas, P. M., Brundin, P., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar5280 · Cited by 287
Van der Perren, A., Gelders, G., Fenyi, A., Bousset, L., Brito, F., Peelaerts, W., Van den Haute, C., Gentleman, S., Melki, R., & Baekelandt, V. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02157-3 · Cited by 277
Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease
Wang, Z., Becker, K., Donadio, V. A., Siedlak, S. L., Yuan, J., Rezaee, M., Incensi, A., Kuzkina, A., Orru, C. D., Tatsuoka, C. M., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3311 · Cited by 268
Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy
Brendel, M., Barthel, H., van Eimeren, T., MAREK, K. L., Beyer, L., Song, M., Palleis, C., Gehmeyr, M., Fietzek, U. M., Respondek, G., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2526 · Cited by 267
Self-citationQuality of life in Parkinson's disease: A systematic review and meta‐analysis of comparative studies
Zhao, N., Yang, Y., Zhang, L., Zhang, Q., Balbuena, L., Ungvari, G. S., Zang, Y., & Xiang, Y. (2020) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13549 · Cited by 267
Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Jellinger, K. A. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1821-9 · Cited by 277
The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases
Rey, N. L., Wesson, D. W., & Brundin, P. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.013 · Cited by 257
Trial of Deferiprone in Parkinson’s Disease
Devos, D., Labreuche, J., Rascol, O., Corvol, J., Duhamel, A., Delannoy, P. G., Poewe, W. H., Compta, Y., Pavese, N., Růžička, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2209254 · Cited by 262
Self-citationFanciulli, A., Stanković, I., Krismer, F., Seppi, K., Levin, J., & Wenning, G. K. (2019) · International review of neurobiology · doi:10.1016/bs.irn.2019.10.004 · Cited by 259
Evolving concepts on bradykinesia
Bologna, M., Paparella, G., Fasano, A. A., Hallett, M., & Berardelli, A. (2019) · Brain · doi:10.1093/brain/awz344 · Cited by 270
Hou, Y.-F., Shan, C., Zhuang, S.-Y., Zhuang, Q.-Q., Ghosh, A., Zhu, K.-C., Kong, X.-K., Wang, S.-M., Gong, Y.-L., Yang, Y.-Y., et al. (2021) · Microbiome · doi:10.1186/s40168-020-00988-6 · Cited by 231
18F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment
Meyer, P. T., Frings, L., Rücker, G., & Hellwig, S. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186403 · Cited by 248
Marsili, L., Rizzo, G., & Colosimo, C. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00156 · Cited by 262
Brabenec, L., Mekyska, J., Galáž, Z., & Rektorová, I. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1676-0 · Cited by 264
The Genetics of Parkinson’s Disease and Implications for Clinical Practice
Day, J. O., & Mullin, S. (2021) · Genes · doi:10.3390/genes12071006 · Cited by 273
Barazzuol, L., Giamogante, F., Brini, M., & Calí, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051772 · Cited by 246
Parkinson’s: a syndrome rather than a disease?
Titova, N., Padmakumar, C., Lewis, S. J. G., & Chaudhuri, К. R. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1667-6 · Cited by 234
Parkinson’s Disease: A Review from Pathophysiology to Treatment
Marino, B. L. B., de Souza, L. R., Sousa, K. P. A., Ferreira, J. V., Padilha, E. C., da Silva, C. H. T. D. P., Taft, C. A., & Hage-Melim, L. I. D. S. (2019) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557519666191104110908 · Cited by 239
Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry
Shao, Y., Li, T., Liu, Z., Wang, X., Xu, X., Li, S., Xu, G., & Le, W. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00425-8 · Cited by 226
Gender differences in Parkinson’s disease: A clinical perspective
Georgiev, D., Hamberg, K., Hariz, M., Forsgren, L., & Hariz, G.-M. (2017) · Acta Neurologica Scandinavica · doi:10.1111/ane.12796 · Cited by 220
Sommerauer, M., Fedorova, T. D., Hansen, A. K., Knudsen, K., Otto, M., Jeppesen, J., Frederiksen, Y., Blicher, J. U., Geday, J., Nahimi, A., et al. (2017) · Brain · doi:10.1093/brain/awx348 · Cited by 217
Physical exercise for people with Parkinson’s disease: a systematic review and network meta-analysis
Ernst, M., Folkerts, A., Gollan, R., Lieker, E., Caro-Valenzuela, J., Adams, A., Cryns, N., Monsef, I., Dresen, A., Roheger, M., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013856.pub2 · Cited by 251
Shen, T., Yue, Y., Ba, F., He, T., Tang, X., Hu, X., Pu, J., Huang, C., Lv, W., Zhang, B., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00437-1 · Cited by 216
Wang, Y., Hu, J., Wu, S., Fleishman, J. S., Li, Y., Xu, Y.-S., Zou, W., Wang, J., Feng, Y., Chen, J., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01720-0 · Cited by 225
Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease
Sawamoto, N., Doi, D., Nakanishi, E., Sawamura, M., Kikuchi, T., Yamakado, H., Taruno, Y., Shima, A., Fushimi, Y., Okada, T., et al. (2025) · Nature · doi:10.1038/s41586-025-08700-0 · Cited by 239
Evolving basic, pathological and clinical concepts in PD
Kalia, L. V., & Lang, A. E. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.249 · Cited by 216
Self-citationMicroglia as modulators of exosomal alpha-synuclein transmission
Xia, Y. F., Zhang, G., Han, C., Ma, K., Guo, X., Wan, F. J., Kou, L., Yin, S., Liu, L., Huang, J., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1404-9 · Cited by 212
Doença de Parkinson: Revisão Clínica e Atualização
Cabreira, V., & Massano, J. (2019) · Acta Médica Portuguesa · doi:10.20344/amp.11978 · Cited by 207
The role of noradrenaline in cognition and cognitive disorders
Holland, N., Robbins, T. W., & Rowe, J. B. (2021) · Brain · doi:10.1093/brain/awab111 · Cited by 216
Jennings, D. L., Siderowf, A. D., Stern, M., Seibyl, J. P., Eberly, S. W., Oakes, D., MAREK, K. L., & for the PARS Investigators (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0985 · Cited by 202
Self-citationTsukita, K., Sakamaki-Tsukita, H., & Takahashi, R. (2022) · Neurology · doi:10.1212/wnl.0000000000013218 · Cited by 218
Resting-state fMRI in Parkinson's disease patients with cognitive impairment: A meta-analysis
Wolters, A. F., van de Weijer, S. C. F., Leentjens, A. F. G., Duits, A., Jacobs, H. I. L., & Kuijf, M. L. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.12.016 · Cited by 214
Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease
Maraki, M. I., Yannakoulia, M., Stamelou, M., Stefanis, L., Xiromerisiou, G., Kosmidis, M. H., Dardiotis, E., Hadjigeorgiou, G. M., Sakka, P., Anastasiou, C. A., et al. (2019) · Movement Disorders · doi:10.1002/mds.27489 · Cited by 195
Clinical Features of Parkinson’s Disease: The Evolution of Critical Symptoms
Váradi, C. (2020) · Biology · doi:10.3390/biology9050103 · Cited by 196
A case of probable Parkinson's disease after SARS-CoV-2 infection
Cohen, M. E., Eichel, R., Steiner‐Birmanns, B., Janah, A., Ioshpa, M., Bar‐Shalom, R., Paul, J. J., Gaber, H., Skrahina, V., Bornstein, N. M., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30305-7 · Cited by 192
Dovonou, A., Bolduc, C., Linan, V. S., Gora, C., Peralta, M. R., & Lévesque, M. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00368-8 · Cited by 218
Effects of COVID‐19 on Parkinson's Disease Clinical Features: A Community‐Based Case‐Control Study
Cilia, R., Bonvegna, S., Straccia, G., Andreasi, N. G., Elia, A. E., Romito, L. M., Devigili, G., Cereda, E., & Eleopra, R. (2020) · Movement Disorders · doi:10.1002/mds.28170 · Cited by 185
Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies
Poggiolini, I., Gupta, V., Lawton, M., Lee, S., El-Turabi, A., Querejeta-Coma, A., Trenkwalder, C., Sixel-Döring, F., Foubert-Samier, A., Pavy-Le Traon, A., et al. (2022) · Brain · doi:10.1093/brain/awab431 · Cited by 191
Self-citationGhosh, A., Tyson, T., George, S., Hildebrandt, E. N., Steiner, J. A., Madaj, Z., Schulz, E., Machiela, E., McDonald, W. G., Galvis, M. L. E., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2210 · Cited by 193
Parkinson's Disease Is Not Simply a Prion Disorder
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1787-16.2017 · Cited by 197
Self-citationTrajectories of prediagnostic functioning in Parkinson’s disease
Darweesh, S. K. L., Verlinden, V. J. A., Stricker, B. H. C., Albert Hofman, D., Koudstaal, P. J., & Ikram, M. A. (2016) · Brain · doi:10.1093/brain/aww291 · Cited by 186
An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders
Ashton, N. J., Hye, A., Rajkumar, A. P., Leuzy, A., Snowden, S. G., Suárez‐Calvet, M., Karikari, T. K., Schöll, M., Joie, R. L., Rabinovici, G. D., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0348-0 · Cited by 185
Luca, C. M. G. D., Elia, A. E., Portaleone, S. M., Cazzaniga, F. A., Rossi, M., Bistaffa, E., Cecco, E. D., Narkiewicz, J., Salzano, G., Carletta, O., et al. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0164-x · Cited by 190
Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder
Stefani, A., Iranzo, Á., Holzknecht, E., Perra, D., Bongianni, M., Gaig, C., Heim, B., Serradell, M., Sacchetto, L., Garrido, A., et al. (2021) · Brain · doi:10.1093/brain/awab005 · Cited by 178
Self-citationParkinson's Disease: A Multisystem Disorder
Costa, H. N., Esteves, A. R., Empadinhas, N., & Cardoso, S. M. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00934-6 · Cited by 205
Precision medicine for disease modification in Parkinson disease
Espay, A. J., Brundin, P., & Lang, A. E. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.196 · Cited by 186
Self-citationMercado, G., Castillo, V., Soto, P., López, N., Axten, J. M., Sardi, S. P., Hoozemans, J. J. M., & Hetz, C. A. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.01.004 · Cited by 183
Natural history of motor symptoms in Parkinson’s disease and the long-duration response to levodopa
Cilia, R., Cereda, E., Akpalu, A. K., Sarfo, F. S., Cham, M., Laryea, R. Y., Obese, V., Oppon, K. J., Sorbo, F. D., Bonvegna, S., et al. (2020) · Brain · doi:10.1093/brain/awaa181 · Cited by 179
Espay, A. J., Schwarzschild, M. A., Tanner, C. M., Fernandez, H. H., Simon, D. K., Leverenz, J. B., Merola, A., Chen‐Plotkin, A. S., Brundin, P., Kauffman, M., et al. (2017) · Movement Disorders · doi:10.1002/mds.26913 · Cited by 179
Self-citationSubtypes of Parkinson’s Disease: What Do They Tell Us About Disease Progression?
Fereshtehnejad, S., & Postuma, R. B. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0738-x · Cited by 189
Self-citation
Metadata
- Authors
- Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., Halliday, G., Goetz, C. G., Gasser, T., Dubois, B., Chan, P., Bloem, B. R., Adler, C. H., & Deuschl, G.
- Affiliations
- Montreal General Hospital (CA)
- German Center for Neurodegenerative Diseases (DE)
- University of Pennsylvania Health System (US)
- Innsbruck Medical University (AT)
- Mount Sinai Hospital (US)
- Philipps University of Marburg (DE)
- University of Navarra‐FIMA Pamplona Spain
- Institute for Neurodegenerative Disorders (US)
- University of California San Diego (US)
- Toronto Western Hospital (CA)
- Neuroscience Research Australia (AU)
- Rush University Medical Center (US)
- Pitié-Salpêtrière Hospital (FR)
- Xuan Wu Hospital of the Capital Medical University (CN)
- Radboud University Nijmegen (NL)
- Mayo Clinic in Arizona (US)
- Christian-Albrechts-Universität zu Kiel (DE)
- Corresponding author
- Postuma, Ronald B.
- Berg, Daniela
- ORCID
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2015-10
- Volume
- 30
- Issue
- 12
- Pages
- 1591-1601
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2112455323
- Cited by
- 7,653
- References
- 34
- Citations by year
- 2026: 1094 · 2025: 1265 · 2024: 1053 · 2023: 932 · 2022: 880 · 2021: 734 · 2020: 686 · 2019: 420 · 2018: 295 · 2017: 193 · 2016: 87 · 2015: 3
- FWCI
- 25.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Movement Disorders (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- DZNE Pub (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Parkinson's disease, diagnostic criteria, Movement Disorder Society criteria, parkinsonism, bradykinesia, resting tremor, rigidity, non-motor symptoms, prodromal Parkinson's disease, exclusion criteria, diagnostic certainty, diagnosis
- MeSH terms
- Humans, Neuropsychological Tests, Parkinson Disease, Reference Standards, Severity of Illness Index, Societies, Scientific
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
